On May 15, 2020, Duke-NUS Medical School, GenScript Biotech, and the Diagnostics Development Hub at Singapore’s Agency for Science, Technology and Research, announced an exclusive agreement to co-develop and manufacture a unique serological coronavirus (COVID-19) detection system known as the surrogate virus neutralisation test (sVNT) or cPassﾙ.

This test was the first in the world that allows rapid detection of neutralising antibodies (NAbs) ﾖ the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection, without the need of live biological materials and biocontainment facility.